240 related articles for article (PubMed ID: 23345581)
21. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.
Hemachandra A; Puls RL; Sirivichayakul S; Kerr S; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher A; Ruxrungtham K
Hum Vaccin; 2010 Oct; 6(10):835-40. PubMed ID: 20864808
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
23. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
24. Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India.
Munusamy Ponnan S; Pattabiram S; Thiruvengadam K; Goyal R; Singla N; Mukherjee J; Chatrath S; Bergin P; T Kopycinski J; Gilmour J; Kumar S; Muthu M; Subramaniam S; Swaminathan S; Prasad Tripathy S; Luke HE
PLoS One; 2019; 14(3):e0213911. PubMed ID: 30921340
[TBL] [Abstract][Full Text] [Related]
25. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
26. Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.
Joachim A; Nilsson C; Aboud S; Bakari M; Lyamuya EF; Robb ML; Marovich MA; Earl P; Moss B; Ochsenbauer C; Wahren B; Mhalu F; Sandström E; Biberfeld G; Ferrari G; Polonis VR
PLoS One; 2015; 10(4):e0118486. PubMed ID: 25874723
[TBL] [Abstract][Full Text] [Related]
27. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
28. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
Cebere I; Dorrell L; McShane H; Simmons A; McCormack S; Schmidt C; Smith C; Brooks M; Roberts JE; Darwin SC; Fast PE; Conlon C; Rowland-Jones S; McMichael AJ; Hanke T
Vaccine; 2006 Jan; 24(4):417-25. PubMed ID: 16176847
[TBL] [Abstract][Full Text] [Related]
29. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
[TBL] [Abstract][Full Text] [Related]
30. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
[TBL] [Abstract][Full Text] [Related]
31. Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.
Frey SE; Peiperl L; McElrath MJ; Kalams S; Goepfert PA; Keefer MC; Baden LR; Lally MA; Mayer K; Blattner WA; Harro CD; Hammer SM; Gorse GJ; Hural J; Tomaras GD; Levy Y; Gilbert P; deCamp A; Russell ND; Elizaga M; Allen M; Corey L
Clin Vaccine Immunol; 2014 Nov; 21(11):1589-99. PubMed ID: 25253665
[TBL] [Abstract][Full Text] [Related]
32. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults.
Mulligan MJ; Russell ND; Celum C; Kahn J; Noonan E; Montefiori DC; Ferrari G; Weinhold KJ; Smith JM; Amara RR; Robinson HL;
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):678-83. PubMed ID: 16831092
[TBL] [Abstract][Full Text] [Related]
33. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.
Hancock G; Morón-López S; Kopycinski J; Puertas MC; Giannoulatou E; Rose A; Salgado M; Hayton EJ; Crook A; Morgan C; Angus B; Chen F; Yang H; Martinez-Picado J; Hanke T; Dorrell L
J Int AIDS Soc; 2017 May; 20(1):21171. PubMed ID: 28537062
[TBL] [Abstract][Full Text] [Related]
35. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
[TBL] [Abstract][Full Text] [Related]
36. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.
García-Arriaza J; Arnáez P; Gómez CE; Sorzano CÓ; Esteban M
PLoS One; 2013; 8(6):e66894. PubMed ID: 23826170
[TBL] [Abstract][Full Text] [Related]
37. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
Currier JR; Ngauy V; de Souza MS; Ratto-Kim S; Cox JH; Polonis VR; Earl P; Moss B; Peel S; Slike B; Sriplienchan S; Thongcharoen P; Paris RM; Robb ML; Kim J; Michael NL; Marovich MA
PLoS One; 2010 Nov; 5(11):e13983. PubMed ID: 21085591
[TBL] [Abstract][Full Text] [Related]
38. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
[TBL] [Abstract][Full Text] [Related]
39. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
[TBL] [Abstract][Full Text] [Related]
40. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.
Gómez CE; Nájera JL; Perdiguero B; García-Arriaza J; Sorzano CO; Jiménez V; González-Sanz R; Jiménez JL; Muñoz-Fernández MA; López Bernaldo de Quirós JC; Guardo AC; García F; Gatell JM; Plana M; Esteban M
J Virol; 2011 Nov; 85(21):11468-78. PubMed ID: 21865377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]